Due to the inordinate delay in the approval of the composite scheme of demerger, continuing uncertainty of receiving the requisite approvals and less than optimum performance of diagnostics business during this period of delay, it may not be suitable for FMHL shareholders to continue with this scheme as the valuation ascribed earlier to diagnostics business may not be appropriate now. Also, FMHL is a strong independent listed company and can continue to operate through a single hospital business model.

The Board of Fortis Malar Hospitals has on 13 June 2018 approved the withdrawal of the Scheme, subject to the approval of the NCLT.